SEGURA

Tom Segura and Christina P. Partner with Comedy Collectibles Startup Jambb to Bring Your Mom’s House NFTs to Fans

Retrieved on: 
Wednesday, January 26, 2022
Technology, Retail, Audio, Video, Social Media, Entertainment, Online, Events, Concerts, Luxury, General Entertainment, Film & Motion Pictures, Celebrity, Software, Communications, TV and Radio, Netflix, YMH, Industry, COVID-19, Christina Pazsitzky, Syfy, TruTV, Twitter, Hannibal, Friends, House, Non-fungible token, Love, NFT, CEO, Ball hog, Television, Music, Entertainment, VH1, Degenerates

We are beyond thrilled to partner with Your Moms House, said Alex DiNunzio, Jambbs co-founder and CEO.

Key Points: 
  • We are beyond thrilled to partner with Your Moms House, said Alex DiNunzio, Jambbs co-founder and CEO.
  • Tom and Christina are favorites of the Jambb team, but even more importantly, Your Moms House was at the top of our communitys wishlist for future content drops.
  • NFTs enable fans to not only consume content digitally, but to own the cultural moments that matter most to them.
  • Christina and I are constantly seeking out unique ways to connect with our listeners, making Jambb a perfect collaborator, said Segura.

Galderma Receives FDA Approval for Restylane® Defyne for Chin Augmentation

Retrieved on: 
Wednesday, February 3, 2021
Medical specialties, Surgery, Oral and maxillofacial surgery, Oral surgery, Clinical medicine, Glycosaminoglycans, Otorhinolaryngology, Restylane, Lidocaine, Chin, Lyft, Subcutaneous

For more information about Restylane Defyne for chin, visit RestylaneUSA.com.

Key Points: 
  • For more information about Restylane Defyne for chin, visit RestylaneUSA.com.
  • The FDA approval of Restylane Defyne for chin adds to Galderma's growing Restylane product portfolio.
  • The Restylane family of products are indicated for patients over the age of 21, and includes Restylane, Restylane-L, Restylane Lyft with Lidocaine, Restylane Silk, Restylane Refyne, Restylane Defyne and Restylane Kysse.
  • Restylane Defyne is also indicated for injection into the mid-to deep dermis (subcutaneous and/or supraperiosteal) for augmentation of the chin region to improve the chin profile in patients with mild to moderate chin retrusion.

Galderma Receives FDA Approval for Restylane® Defyne for Chin Augmentation

Retrieved on: 
Monday, February 1, 2021
Medical specialties, Surgery, Oral and maxillofacial surgery, Oral surgery, Clinical medicine, Glycosaminoglycans, Otorhinolaryngology, Restylane, Lidocaine, Chin, Lyft, Subcutaneous

For more information about Restylane Defyne for chin, visit RestylaneUSA.com.

Key Points: 
  • For more information about Restylane Defyne for chin, visit RestylaneUSA.com.
  • The FDA approval of Restylane Defyne for chin adds to Galderma's growing Restylane product portfolio.
  • The Restylane family of products are indicated for patients over the age of 21, and includes Restylane, Restylane-L, Restylane Lyft with Lidocaine, Restylane Silk, Restylane Refyne, Restylane Defyne and Restylane Kysse.
  • Restylane Defyne is also indicated for injection into the mid-to deep dermis (subcutaneous and/or supraperiosteal) for augmentation of the chin region to improve the chin profile in patients with mild to moderate chin retrusion.